Enduring Effects of Microstent Use
Randomized trials of the Hydrus Micro-stent (HMS) have found that it significantly reduces IOP and medication burden through two years following surgery for primary open-angle glaucoma (POAG). By year 3, recipients of the HMS were less likely to require additional incision surgery for glaucoma. Subsequently, Ahmed et al. looked at five-year outcomes of the HORIZON trial, in which cataract surgery alone was compared with combined cataract/glaucoma surgery with the HMS.